- Home
- LSF vs IXHL Comparison
LSF vs IXHL Comparison
Compare LSF & IXHL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | LSF | IXHL |
|---|---|---|
| Founded | 2015 | 2001 |
| Country | United States | Australia |
| Employees | N/A | N/A |
| Industry | Packaged Foods | |
| Sector | Consumer Staples | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 23.8M | 97.6M |
| IPO Year | 2020 | 2024 |
Fundamental Metrics
Financial Performance| Metric | LSF | IXHL |
|---|---|---|
| Price | $2.78 | $3.92 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 1 | 0 |
| Target Price | ★ $12.00 | N/A |
| AVG Volume (30 Days) | 66.9K | ★ 6.3M |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 75.28 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $43,295,137.00 | $12,000.00 |
| Revenue This Year | $15.87 | N/A |
| Revenue Next Year | $14.98 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ 26.50 | N/A |
| 52 Week Low | $1.98 | $0.11 |
| 52 Week High | $7.94 | $5.17 |
Technical Indicators
Market Signals| Indicator | LSF | IXHL |
|---|---|---|
| Relative Strength Index (RSI) | 44.30 | 89.14 |
| Support Level | $2.46 | $0.32 |
| Resistance Level | $2.76 | N/A |
| Average True Range (ATR) | 0.22 | 0.13 |
| MACD | -0.02 | 0.39 |
| Stochastic Oscillator | 34.68 | 76.27 |
Price Performance
Historical ComparisonAbout LSF Laird Superfood Inc.
Laird Superfood Inc is engaged in the business of manufacturing and marketing differentiated plant-based and functional foods. The product portfolio includes Coffee creamers, Hydration products and beverage-enhancing supplements, Harvest snacks and various other food items, and Coffee, tea, and hot chocolate products.
About IXHL Incannex Healthcare Inc.
Incannex Healthcare Inc is a clinical stage pharmaceutical company developing medical cannabis products for the treatment of Obstructive Sleep Apnea (OSA), Traumatic Brain Injury (TBI)/Concussion, Rheumatoid Arthritis, Inflammatory Bowel Disease, and Inflammatory Lung Conditions. The company has an Australian license to import, export, and distribute medicinal cannabis products and has launched a line of cannabinoid products. The Company operates and manages its business as one reportable and operating segment, which is the Research and Development of the use of psychedelic medicine and therapies.